Top 10 Companies in the PLGA Market (2026): Market Leaders Powering Global Therapeutics

MARKET INSIGHTS

Global PLGA market was valued at USD 91.24 million in 2025. The industry is expected to rise from an estimated USD 104.2 million in 2026 to USD 226 million by 2034, reflecting a steady trajectory in the forecast period.

PLGA, or Poly(lactic‑co‑glycolic acid), is a biodegradable and biocompatible copolymer that serves as the backbone for controlled drug delivery systems and medical implants. Its natural monomers—lactic acid and glycolic acid—contribute to minimal toxicity, while the amorphous structure allows degradation rates to be fine‑tuned by adjusting the lactide‑to‑glycolide ratio. In 2024, global production reached approximately 3,452 kg, with an average market price of around USD 25,622 per kilogram, underscoring its specialty status.

The market’s upward movement is largely attributable to PLGA’s expanding role in advanced pharmaceutical formulations, particularly in long‑acting injectables (LAIs) and implantable drug delivery systems that enhance patient adherence. Its application in resorbable medical devices, such as sutures and orthopedic fixation aids, eliminates the need for secondary removal surgeries, aligning with the shift toward minimally invasive procedures. Nonetheless, the market faces challenges stemming from stringent Good Manufacturing Practice (GMP) requirements and complex scale‑up processes necessary for regulatory approvals.

PLGA Market – View in Detailed Research Report

Top 10 Companies in the PLGA Market

1️⃣ Evonik Industries

Headquarters: Essen, Germany
Key Offering: RESOMER® PLGA polymers for drug delivery and implantable devices

Evonik has positioned itself as the benchmark for high‑purity PLGA, leveraging a vertically integrated supply chain that spans polymerization, purification, and quality assurance. The company’s deep expertise in controlled polymerization grants it a competitive edge in delivering consistent molecular weight profiles and copolymer ratios, essential for regulatory compliance.

Sustainability & Growth Initiatives:

• Investment in greener polymerization routes to reduce solvent usage
• Partnerships with biopharmaceuticals to develop next‑generation LAIs
• Commitment to circular manufacturing through monomer recycling programs

2️⃣ Corbion

Headquarters: Heerlen, Netherlands
Key Offering: Customizable PLGA grades for drug delivery and tissue engineering

Corbion’s specialization in lactic acid chemistry enables it to produce high‑grade PLGA with precise lactide‑to‑glycolide ratios. The firm’s focus on flexible manufacturing capacities allows rapid adaptation to emerging therapeutic demands, particularly in the regenerative medicine segment.

Sustainability & Growth Initiatives:

• Integration of bio‑based monomer sourcing to lower carbon footprint
• Collaborations with academic institutions for scaffold development
• Expansion of regional production sites in Asia to meet local demand

3️⃣ PCAS

Headquarters: Paris, France
Key Offering: High‑purity PLGA for pharmaceutical and medical device applications

PCAS brings advanced fine‑chemical synthesis capabilities to the PLGA market, enabling the production of tailored polymer grades that meet stringent regulatory standards. Its agile manufacturing model supports rapid scale‑up for clinical trials and commercial launches.

Sustainability & Growth Initiatives:

• Adoption of renewable energy sources in production facilities
• Development of end‑capped PLGA variants to improve drug release control
• Strategic alliances with contract manufacturing organizations (CMOs)

4️⃣ Mitsui Chemicals

Headquarters: Tokyo, Japan
Key Offering: PLGA polymers for long‑acting therapeutics and implantable devices

Mitsui’s strong presence in the Asian market is underpinned by its robust supply chain for lactic and glycolic acids. The company emphasizes precision polymerization to deliver consistent degradation kinetics, a critical factor for device performance.

Sustainability & Growth Initiatives:

• Investments in advanced polymerization reactors to improve energy efficiency
• Collaboration with Japanese pharmaceutical firms on LAI pipelines
• Support for local monomer production to reduce import dependencies

5️⃣ SDSYXS

Headquarters: Seoul, South Korea
Key Offering: Specialty PLGA grades for drug delivery and regenerative applications

Operating within a dynamic South Korean biotech ecosystem, SDSYXS focuses on delivering high‑performance PLGA with low residual monomer content, meeting the rigorous demands of biologics and gene therapies.

Sustainability & Growth Initiatives:

• Implementation of closed‑loop solvent recovery systems
• Partnerships with Korean universities for scaffold research
• Expansion of export capabilities to neighboring markets

6️⃣ Jinan Daigang Biomaterial

Headquarters: Jinan, China
Key Offering: Cost‑effective PLGA for drug delivery and medical devices

Jinan Daigang has carved out a niche by providing scalable PLGA solutions that balance performance with affordability, catering to China’s growing domestic pharmaceutical industry.

Sustainability & Growth Initiatives:

• Adoption of agricultural‑derived monomer sources to reduce raw material costs
• Collaboration with local CMOs to streamline product development cycles
• Investment in quality management systems aligned with ISO 13485

7️⃣ Bachem

Headquarters: Horgen, Switzerland
Key Offering: High‑purity PLGA for pharmaceutical development

Bachem’s reputation in fine chemicals enables it to produce PLGA with exceptional purity, supporting early‑stage drug discovery and pre‑clinical testing.

Sustainability & Growth Initiatives:

• Use of renewable feedstocks for monomer synthesis
• Integration of digital process analytics for real‑time quality control
• Partnerships with European pharma companies for joint R&D

8️⃣ Envision Polymer

Headquarters: San Diego, USA
Key Offering: Custom PLGA formulations for drug delivery and medical devices

Envision Polymer specializes in tailoring polymer properties to meet specific therapeutic needs, providing rapid turnaround for experimental and commercial projects.

Sustainability & Growth Initiatives:

• Development of solvent‑free polymerization processes
• Collaborations with biotech firms on targeted delivery systems
• Expansion of U.S. manufacturing capacity to reduce lead times

9️⃣ Bio‑Techne

Headquarters: San Diego, USA
Key Offering: PLGA‑based drug delivery platforms for biologics

Bio‑Techne leverages its expertise in biologics to produce PLGA that supports controlled release of proteins and peptides, addressing the growing demand for biologic therapeutics.

Sustainability & Growth Initiatives:

• Investment in scalable manufacturing for biologic delivery
• Partnerships with global pharma for pipeline development
• Focus on reducing environmental impact through waste minimization

🔟 Sumitomo Chemical

Headquarters: Osaka, Japan
Key Offering: PLGA polymers for advanced drug delivery and implantable devices

Sumitomo Chemical combines extensive polymer chemistry expertise with a strong distribution network, enabling it to deliver PLGA products that meet diverse application requirements.

Sustainability & Growth Initiatives:

• Implementation of green chemistry principles in polymer synthesis
• Collaboration with Japanese medical device manufacturers on resorbable implants
• Expansion of regional R&D centers to accelerate innovation

PLGA Market – View in Detailed Research Report

PLGA Market – View in Detailed Research Report

Outlook

The trajectory of the PLGA market is shaped by the continued adoption of long‑acting injectables and implantable drug delivery systems, which offer tangible benefits in patient adherence and therapeutic consistency. The integration of PLGA into resorbable medical devices further expands its footprint, particularly in orthopedics and cardiovascular applications where device removal is undesirable. Regulatory momentum and investment in advanced manufacturing technologies are expected to sustain the market’s upward trend.

Future Trends

Key emerging trends include the application of PLGA in regenerative medicine, where its compatibility with 3D printing and bioprinting technologies opens new avenues for patient‑specific scaffolds. In oncology, PLGA nanoparticles are advancing as targeted delivery vehicles that can localize chemotherapeutic agents to tumor sites, potentially reducing systemic toxicity. The continued refinement of end‑capped and modified PLGA variants will enhance control over degradation rates and drug release kinetics, positioning the polymer as a cornerstone for next‑generation therapeutics.